Comparative Study Between Immediate and Deferred Stenting in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202502600494743

Enrollment

100

Registered

2025-02-17

Start date

2021-09-14

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiology

Interventions

Deferred Stenting in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention

Immediate Stenting in Patients with STEMI Undergoing Primary Percutaneous Coronary Inte

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients presenting with STEMI within 12 hours from the symptom onset characteristic symptoms of typical chest pain new ST elevation at the J-point in at least two contiguous leads: =2.5 mm in men <40 years, =2 mm in men =40 years, new ST elevation at the J-point in at least two contiguous leads =1.5 mm in women in leads V2–V3 and/or =1 mm in the other leads the absence of left ventricular hypertrophy or left bundle branch block [LV] hypertrophy or left bundle branch block [LBBB]).

Exclusion criteria

Exclusion criteria: undergoing primary PCI for stent thrombosis, AMI presenting beyond 12 hours following the onset of symptoms, history of coronary Artery Bypass Grafting (CABG)/MI history of cardiogenic shock.

Design outcomes

Primary

Measure	Time frame
monitoring of cardiac arrhythmias (premature ventricular beats, ventricular tachycardia, atrial fibrillation, heart block, premature atrial beats) and assessment of QT dispersion. ST resolution at 60 minutes (detected by ECG). -Total hospital stay period in days. -Incidences of MACE including cardiac death, nonfatal reinfarction (when ST-elevation=1 mm recurs or new pathognomonic Q waves appear in at least two contiguous leads with ischemic symptoms and require more than 20% increase of the cTn value in the second sample), stroke and heart failure (either new onset or worsening after revascularization). -The occurrence of contrast-induced nephropathy (an increase of 25% or more, or an absolute increase of 0.5 mg/dl or more in serum creatinine from baseline value, at 48–72 h following the exposure to contrast media). -Major bleeding (requiring transfusion).	—

Measure

Time frame

monitoring of cardiac arrhythmias (premature ventricular beats, ventricular tachycardia, atrial fibrillation, heart block, premature atrial beats) and assessment of QT dispersion. ST resolution at 60 minutes (detected by ECG). -Total hospital stay period in days. -Incidences of MACE including cardiac death, nonfatal reinfarction (when ST-elevation=1 mm recurs or new pathognomonic Q waves appear in at least two contiguous leads with ischemic symptoms and require more than 20% increase of the cTn value in the second sample), stroke and heart failure (either new onset or worsening after revascularization). -The occurrence of contrast-induced nephropathy (an increase of 25% or more, or an absolute increase of 0.5 mg/dl or more in serum creatinine from baseline value, at 48–72 h following the exposure to contrast media). -Major bleeding (requiring transfusion).

—

Secondary

Measure	Time frame
Occurrence of MACE (cardiac death, reinfarction, stroke, and heart failure). ECG (rhythm and ischemic changes). Echocardiography (assessment of LV dimensions and function, the presence & severity of mitral regurgitation).	—

Countries

Egypt

Contacts

Public ContactMahmoud Abdul Baset

Professor of cardiology AlAzhar uiversity Assiut

elhawycardio77@gmail.com+201112786731

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026